North America HLA Typing for Transplant Market (2025-2030)
The North America HLA Typing for Transplant Market was valued at $506.1 Million in 2025 and projected to reach to $688.5 Million by 2030, representing a compound annual growth rate of 6.3%. North America's HLA typing for transplant market is positioned for steady growth through 2030, supported by increasing organ transplant procedures, aging populations requiring transplantation, and healthcare systems' commitment to improving graft survival rates.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America HLA Typing for Transplant Market Trends and Insights
- In North America, the expansion is driven by increasing organ transplant volumes, rising adoption of advanced molecular typing technologies, and strengthened regulatory frameworks supporting transplant compatibility testing.
- North America maintains a mature healthcare infrastructure with high investment in precision medicine, positioning the region as a leader in HLA typing innovation and clinical implementation. The North America market benefits from well-established transplant networks, including UNOS coordination in the United States and Trillium Gift of Life Network in Canada, which mandate rigorous HLA compatibility protocols.
- North America's aging population and prevalence of end-stage organ disease continue to drive demand for transplant procedures and associated HLA typing services.
- Between 2025 and 2030, North America is expected to see accelerated adoption of next-generation sequencing (NGS) and high-resolution typing methods, further supporting market growth..
Key Market Statistics
- CAGR (2025-2030) 6.3% CAGR
- Market Size, 2025 ~USD 506.1 Million
- Forecast, 2030 ~USD 688.5 Million
- Geography North America
North America HLA Typing for Transplant Market Overview
Market Valuation & Growth :
North America's HLA typing for transplant market is valued at $506.1 million in 2025 and is projected to reach $688.5 million by 2030, with a robust CAGR of 6.3%, outpacing the global average of 6%.
US Market Dominance :
The United States represents the largest market segment in North America with $665.2 million in market size, driven by advanced healthcare infrastructure, high transplant volumes, and significant investment in molecular typing technologies.
Molecular Technology Adoption :
North American transplant centers are increasingly adopting advanced molecular HLA typing methods over traditional serological approaches, improving transplant compatibility rates and patient outcomes across the region.
Regulatory & Clinical Support :
Strengthened regulatory frameworks and clinical guidelines in North America support expanded HLA typing protocols, while rising organ transplant volumes and waitlist management drive consistent demand for typing services.
North America HLA Typing for Transplant Market Dynamics
- The region benefits from mature healthcare infrastructure, high adoption of precision medicine technologies, and robust reimbursement policies that incentivize advanced typing methodologies. Key growth drivers include expanding transplant programs, integration of next-generation sequencing (NGS) platforms, and enhanced pre-transplant compatibility testing protocols.
- North American transplant centers continue to invest in laboratory automation and molecular diagnostics, while regulatory bodies maintain stringent standards that favor comprehensive HLA typing.
- This combination of clinical demand, technological advancement, and supportive healthcare policies ensures sustained market expansion through the forecast period..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- North America's HLA typing market is valued at $506.1 million in 2025 and will reach $688.5 million by 2030, growing at 6.3% CAGR.
- North America's mature transplant infrastructure and regulatory mandates drive consistent demand for HLA compatibility testing across organ types.
- Advanced molecular typing technologies, particularly NGS, are accelerating adoption in North America's leading transplant centers and laboratories.
- North America's aging population and high prevalence of end-stage organ disease sustain long-term growth in transplant procedures and HLA typing services.
HLA Typing for Transplant Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INDEPENDENT REFERENCE LABORATORIES (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 1.05 (2025) |
| Revenue Forecast (Billions) | ~USD 1.4 (2030) |
| Segments Covered | Product & Service, Technology, Type, Application, Transplant Type, End User |
North America HLA Typing for Transplant Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Technology
- Molecular Assays
- Non-Molecular Assays
By Type
- Antibody Screening
- Chimerism Monitoring
- Next-Generation Sequencing
- Other Diagnostic Applications
- Other Pcr-Based Molecular Assays
- Other Sequencing-Based Molecular Assays
- Pcr-Based Molecular Assays
- Real-Time Pcr
- Sanger Sequencing
- Sequence-Specific Oligonucleotide-Pcr
- Sequence-Specific Primer-Pcr
- Sequencing-Based Molecular Assays
By Application
- Diagnostic Applications
- Research Applications
By Transplant Type
- Soft-Tissue Transplants
- Solid Organ Transplants
- Stem Cell Transplants
By End User
- Hospitals & Transplant Centers
- Independent Reference Laboratories
- Research Laboratories & Academic Institutes
Target Audience
- Transplant Diagnostic Companies : Manufacturers and service providers of HLA typing solutions need North America-specific market data to optimize product positioning, pricing strategies, and market penetration in this high-value region.
- Hospital & Transplant Centers : Transplant programs and hospital laboratory directors require market insights to benchmark their HLA typing capabilities, evaluate technology investments, and understand competitive offerings in North America.
- In Vitro Diagnostics (IVD) Manufacturers : IVD companies developing HLA typing reagents and platforms need regional market analysis to guide R&D priorities, regulatory strategies, and commercial expansion in North American markets.
- Healthcare Investors & Consultants : Investment firms and management consultants analyzing the transplant diagnostics sector require North America-specific market data to evaluate acquisition targets, partnership opportunities, and growth potential.
- Regulatory & Policy Bodies : Healthcare regulators and policy organizations in North America benefit from market intelligence to inform clinical guidelines, reimbursement policies, and standards for HLA typing in transplantation.
Key Companies in the North America HLA Typing for Transplant Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Instruments,Reagents,Software, |
| QUIDEL CORPORATION | United States | Public Company | Instruments (Transfusion & Molecular Platforms used in HLA/compatibility workflows),Reagents & Consumables (Antibody Screening, Donor Typing, Molecular Assays),Software & Informatics, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing,Sanger-based HLA typing, |
| ILLUMINA, INC. | United States | Public Company | NGS instruments,NGS reagents and consumables,Software and DRAGEN-based analysis, |
| QIAGEN | Netherlands | Public Company | Reagents & Assays (PCR, NGS, Sanger HLA, immune response),Instruments (PCR, NGS, sample prep, QC),Software & Bioinformatics (HLA typing, chimerism, data analysis), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Instruments (PCR, real-time, supporting platforms),Reagents & consumables for HLA typing and chimerism,Software & informatics for transplant workflows, |
| CAREDX, INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing (AlloSeq Tx and related),Sanger-based HLA typing, |
| DIASORIN S.P.A. | Italy | Public Company | Reagents and assays (HLA-related and transplant-adjacent),Instruments and platforms (LIAISON, Simplexa, xMAP-based systems),Software and informatics for transplant workflows, |
| BECTON, DICKINSON AND COMPANY | United States | ||
| EUROBIO SCIENTIFIC | France | Public Company | Reagents (PCR, NGS, Sanger),Software (HLA typing, data analysis),Instruments and related hardware, |
KINDRED HEALTHCARE INC.
Kindred Healthcare Inc. is a large private healthcare services company founded in 1985 in the United States, employing 64,200 people. The company operates across multiple healthcare service segments.
QUIDEL CORPORATION
Quidel Corporation is a publicly traded diagnostic company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic testing solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large publicly traded life sciences company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded genomics company founded in 1998 in the United States with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN
QIAGEN is a publicly traded molecular diagnostics company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample and assay technologies for molecular testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded life sciences company founded in 1952 in the United States with 7,450 employees. The company manufactures and distributes clinical diagnostic products and laboratory reagents.
CAREDX, INC.
CareDx, Inc. is a publicly traded molecular diagnostics company founded in 1998 in the United States with 763 employees. The company specializes in transplant diagnostics and precision medicine solutions.
DIASORIN S.P.A.
DiaSorin S.p.A. is a publicly traded Italian diagnostics company founded in 1968 with 3,242 employees. The company specializes in immunodiagnostic and molecular diagnostic products.
BECTON, DICKINSON AND COMPANY
Insufficient data provided for company description.
EUROBIO SCIENTIFIC
Eurobio Scientific is a publicly traded French diagnostics company founded in 1997 with 343 employees. The company develops and distributes in vitro diagnostic products.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 665.2 Million |
| Canada | USD 23.38 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into North America's HLA typing market with country-level breakdowns for the US and Canada, enabling precise market sizing and opportunity identification within this high-value region.
- Growth Trajectory Analysis : Understand the 6.3% CAGR growth dynamics specific to North America, with forecasts through 2030 to support strategic planning and investment decisions in transplant diagnostics.
- Technology Adoption Trends : Access North America-specific data on molecular typing technology adoption rates, NGS implementation, and the shift from traditional serological methods in leading transplant centers.
- Competitive Landscape Intelligence : Identify key players, market consolidation patterns, and competitive strategies specific to North American transplant laboratories and diagnostic service providers.
- Regulatory & Reimbursement Insights : Understand North American regulatory frameworks, reimbursement policies, and clinical guidelines that drive HLA typing adoption and influence market dynamics across the US and Canada.
Frequently asked questions
What is the current market size of HLA typing for transplants in North America?
North America's HLA typing for transplant market is valued at $506.1 million in 2025 and is expected to grow to $688.5 million by 2030.
What is the projected growth rate for HLA typing in North America?
North America's HLA typing market is projected to grow at a compound annual growth rate (CAGR) of 6.3% from 2025 to 2030.
What factors are driving HLA typing market growth in North America?
North America's market growth is driven by increasing organ transplant volumes, adoption of advanced molecular typing technologies, regulatory mandates, and an aging population with high end-stage organ disease prevalence.
Which technologies are gaining adoption in North America's HLA typing market?
North America is seeing accelerated adoption of next-generation sequencing (NGS) and high-resolution typing methods, which offer improved accuracy and faster turnaround times for transplant compatibility assessment.
How do North America's transplant networks influence HLA typing demand?
North America's established transplant networks, including UNOS in the United States and Trillium Gift of Life Network in Canada, mandate rigorous HLA compatibility protocols that drive consistent demand for typing services.
RESEARCH METHODOLOGY
This study analyzed market variables related to small and medium-sized businesses and major corporations to balance primary and secondary research for the human leukocyte antigen (HLA) typing for transplant market. The next phase involved conducting primary research with industry experts along the value chain to validate the findings, assumptions, and market sizing. Several methodologies were employed to estimate the overall market size, including both top-down and bottom-up approaches. This study focuses on key market segments, emerging trends, regulatory frameworks, and competitive environments. It also examines leading market players and their strategies within this sector. In conclusion, the total market size was determined using top-down and bottom-up approaches and data triangulation to arrive at the final figure. Ongoing primary research was conducted throughout the study to validate and test each hypothesis.
Secondary Research
During the study, secondary research utilized a variety of sources, including directories and databases such as Bloomberg Businessweek, D&B Hoovers, and Factiva. Additional materials included white papers, annual reports, SEC filings, and investor presentations. This research approach collects and generates data that offers comprehensive, technical, and market-focused insights into the HLA typing for transplant market. The data provides information on key players and market segmentation based on recent industry trends and significant market developments. Additionally, a database of leading industry figures was created through this secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the HLA typing for transplant market. The primary sources from the demand side include medical OEMs, CDMOs, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*Others include distributors, suppliers, product managers, business development managers, marketing managers, and sales managers.
Note: Companies are categorized into tiers based on their total revenue. As of 2024, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global HLA typing for transplant market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA typing for transplants business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players/OEMs operating in the HLA typing for transplant market
- Mapping the annual revenue generated by major global players from the HLA typing segment (or the nearest reported business unit/product category)
- Revenue mapping of top players to cover at least ~75% of the global market share as of 2024
- Extrapolation of the revenue mapping of major players to derive the global value of the market
- Extrapolating the global value of the HLA typing for transplant market.
- Summation of market value for all segments and subsegments to achieve the actual value of the global HLA typing for transplant market
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global HLA typing for transplant market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, top-down and bottom-up approaches validated the HLA typing for transplant market.
Market Definition
HLA typing assays are critical in transplant immunology, as they facilitate the identification of HLA antigens essential for assessing donor-recipient compatibility and mitigating the risk of alloimmune rejection. These assays are pivotal in donor-recipient cross-matching, subject profiling, genotyping, and various diagnostic applications. Recent advancements in HLA typing technology, which enable high-resolution typing, afford precise delineation of HLA allele variations. This increased accuracy significantly enhances the predictive capability for transplant outcomes, thereby minimizing rejection and graft-versus-host disease incidence. As a result, these innovations are instrumental in making transplantation a more feasible and successful therapeutic option for patients.
Stakeholders
- Manufacturers of HLA typing products for transplant
- Distributors & suppliers of HLA typing products for transplant
- Hospitals, Transplant Centers, reference laboratories, Cord Blood Banks
- Research Laboratories and Academic Institutes
- Organ Procurement Organizations (OPOs)
- Non-government organizations
- Government regulatory authorities
- Contract manufacturers and third-party suppliers
- Clinical research organizations (CROs)
- Government and non-governmental regulatory authorities
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the HLA typing for transplant market based on product & service, technology, application, transplant type, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing for transplant market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global HLA typing for transplant market
- To provide an average selling price trend for the target product categories in HLA typing for transplant market
- To analyze key growth opportunities in the global HLA typing for transplant market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), the Asia Pacific (Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key players in the global HLA typing for transplant market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global HLA typing for transplant market, such as product launches, agreements, expansions, and acquisitions
Get the Full HLA Typing for Transplant Market Report
Full forecast, segment splits, and company analysis for all HLA Typing for Transplant Market.
- US HLA Typing for Transplant Market
- Canada HLA Typing for Transplant Market
- Germany HLA Typing for Transplant Market
- UK HLA Typing for Transplant Market
- France HLA Typing for Transplant Market
- Spain HLA Typing for Transplant Market
- Italy HLA Typing for Transplant Market
- China HLA Typing for Transplant Market
- India HLA Typing for Transplant Market
- Japan HLA Typing for Transplant Market
- Australia HLA Typing for Transplant Market
- South Korea HLA Typing for Transplant Market
- Brazil HLA Typing for Transplant Market
- Mexico HLA Typing for Transplant Market
- Rest Of Europe HLA Typing for Transplant Market
- Rest Of Asia Pacific HLA Typing for Transplant Market
- Rest Of Latin America HLA Typing for Transplant Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
